Arbutus Biopharma Corporation (ABUS)

NASDAQ: ABUS · IEX Real-Time Price · USD
2.47
-0.03 (-1.20%)
At close: Aug 11, 2022 4:00 PM
2.48
+0.01 (0.40%)
Pre-market: Aug 12, 2022 8:34 AM EDT
-1.20%
Market Cap 370.38M
Revenue (ttm) 33.37M
Net Income (ttm) -76.10M
Shares Out 149.95M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 786,261
Open 2.52
Previous Close 2.50
Day's Range 2.44 - 2.53
52-Week Range 1.93 - 6.50
Beta 2.24
Analysts Buy
Price Target 6.63 (+168.4%)
Earnings Date Aug 4, 2022

About ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid... [Read more...]

Industry Biotechnology
CEO William Collier
Employees 85
Stock Exchange NASDAQ
Ticker Symbol ABUS
Full Company Profile

Financial Performance

In 2021, ABUS's revenue was $10.99 million, an increase of 58.92% compared to the previous year's $6.91 million. Losses were -$76.25 million, 19.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ABUS stock is "Buy." The 12-month stock price forecast is 6.63, which is an increase of 168.42% from the latest price.

Price Target
$6.63
(168.42% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Key milestones across our chronic hepatitis B virus (cHBV) and  pan-coronavirus programs remain on track

Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update

WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel t...

Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor

Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences' core inhibitor, and nucleos(t)ide analog continues with data expected in 2H 2022

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B

JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on Arbutus Biopharma Corp (NASDAQ: ABUS) after data presentation at the European Association for the St...

Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB...

AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients

Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022

Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ET

Arbutus to Participate in June Investor Conferences

WARMINSTER, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel t...

Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual M...

WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel th...

Arbutus to Present at H.C. Wainwright Global Investment Conference

WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel th...

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update

Key milestones across our chronic hepatitis B virus (cHBV) and  pan-coronavirus programs remain on track

Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update

WARMINSTER, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel ...

This 1 New Threat Could Punish Moderna Stock

A new chapter of a long-standing legal battle is starting.

Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

Anticipate reporting data from four clinical trials in chronically infected HBV patients in 2022

Arbutus, Genevant sue Moderna, citing patent infringement

Shares of Arbutus Biopharma Corp. ABUS, +7.21% gained 11.0% in premarket trading on Monday after the company said it is suing Moderna Inc. MRNA, +1.70% for infringing on several patents that relate to M...

Other symbols: MRNA

Arbutus files patent infringement lawsuit against Moderna

Arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for infringement of patents related to its COVID-19 vaccine.

Other symbols: MRNA

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna

WARMINSTER, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel t...

Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna

VANCOUVER, British Columbia and CAMBRIDGE, Mass. and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company, and Arbutus Biopharma Corporation (...

Other symbols: MRNA

Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel t...

What's the Outlook for Arbutus Biopharma?

The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.

Arbutus Announces 2022 Corporate Objectives and Provides Financial Update

Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies

Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference

WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializi...